The Mitochondria Doctor: This Reverses Gray Hair, Makes You Feel Young Again & Fixes Disease!

Neuroimaging shows that some elderly individuals have full-blown Alzheimer's disease with zero brain protein deposits, while others have high amyloid plaque and tau tangle burdens with completely normal cognition.

"You can have people in their 60s and their 70s and their 80s, zero protein deposit in the brain. We can image this now pretty well with neuroimaging. You can have people zero protein deposit in the brain, and they have full-blown Alzheimer's and dementia. And you have the other extreme, people with loads of amyloid plaques and tau tangles, completely normal cognition." (said at 1:04:43)

The claim bundles two assertions with conflicting accuracy: 1. Dementia with 'zero protein deposits': Contradicted. Under current consensus criteria (such as the NIA-AA Research Framework), Alzheimer's disease is biologically defined by amyloid-β and tau pathology. While older adults can present with dementia or cognitive impairment without amyloid or tau deposits, these syndromes represent non-Alzheimer's etiologies (e.g., vascular dementia, frontotemporal lobar degeneration, or LATE/TDP-43), not 'full-blown Alzheimer's disease'. 2. High plaque/tangle burden with normal cognition: Supported. Extensive neuroimaging and cohort data (e.g., the Mayo Clinic Study of Aging) demonstrate that substantial amyloid plaque and tau tangle deposition occurs in cognitively unimpaired older individuals (preclinical Alzheimer's disease), representing cognitive resilience or early-stage pathological accumulation prior to clinical symptom onset. Following the evaluation rule to grade based on the least accurate bundled assertion, the overall verdict is contradicted.

• contradicts: NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. (Alzheimer's & dementia : the journal of the Alzheimer's Association 2018) · cited 10715x in the literature

  "Although it is possible that β-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia." (abstract, conclusions)

  pubmedfull study (doi)
• supports: Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the Nat… (JAMA neurology 2019) · cited 311x in the literature

  "The prevalence of biological Alzheimer disease was greater than clinically defined probable Alzheimer disease for women and men. Among women, these values were 10% (95% CI, 6%-14%) vs 1% (95% CI, 1%-1%) at age 70 years and 33% (95% CI, 25%-41%) vs 10% (95% CI, 9%-12%) at age 85 years (P < .001)... This difference is mostly driven by asymptomatic individuals with biological Alzheimer disease." (abstract, results, passage verified)

  pubmedfull study (doi)

GDF15 is expressed by peripheral organs but not by the brain, whereas its receptor (GFRAL) is located exclusively in the brainstem area postrema.

"and that protein can be made by any organ in the body except one. The brain... Where is the receptor? Right?... Only in one organ in the body... Yeah, so in the brainstem. The The brainstem is where kind of the the basic survival systems of the body are and there's a region in the brainstem called the area postrema." (said at 1:49:14)

The speaker bundles two distinct assertions: 1) that GDF15 is produced by every organ except the brain, and 2) that its receptor (GFRAL) is located exclusively in the brainstem area postrema. The receptor localization claim is supported: multiple landmark studies demonstrate that GFRAL expression is restricted almost exclusively to neurons in the area postrema and nucleus of the solitary tract (AP/NTS) in the caudal brainstem. However, the claim that the brain cannot or does not produce GDF15 is contradicted: GDF15 is actively expressed within the central nervous system (by neurons, microglia, and astrocytes), particularly in response to aging, neuroinflammation, cellular stress, and neurodegenerative diseases. Following grading rules for bundled assertions, the overall claim receives the verdict of its least accurate component.

• supports: Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. (Nature 2017) · cited 626x in the literature

  "Here we identify glial cell-derived neurotrophic factor (GDNF) receptor alpha-like (GFRAL) as a brainstem-restricted receptor for growth and differentiation factor 15 (GDF15)... GDF15 activates GFRAL-expressing neurons localized exclusively in the area postrema and nucleus tractus solitarius of the mouse brainstem." (abstract, results)

  pubmedfull study (doi)
• contradicts: The expression pattern of GDF15 in human brain changes during aging and in Alzheimer's dis… (Frontiers in aging neuroscience 2022) · cited 42x in the literature

  "GDF15 was expressed in different brain areas and seems to be predominantly localized in neurons... Although GDF15 seems not to be a reliable CSF marker for AD, it is highly expressed in aging and AD brains, likely as a part of stress response aimed at counteracting mitochondrial dysfunction and neuroinflammation." (abstract, results)

  pubmedfull study (doi)
• supports: GDNF family receptor alpha-like (GFRAL) expression is restricted to the caudal brainstem. (Molecular metabolism 2025) · cited 25x in the literature

  "In mice we found readably detectable Gfral mRNA within the AP/NTS but not within other brain sites. Within peripheral tissues, we failed to detect any Gfral-labelled cells in the vast majority of examined tissues and when present, were extremely rare... Through highly sensitive and selective technologies we show Gfral expression is overwhelmingly restricted to the brainstem" (abstract, results, passage verified)

  pubmedfull study (doi)